Aminotetrahydroindazoloacetic acids
AssigneeHoffmann-La Roche Inc.
InventorsLi Chen, Fariborz Firooznia, Paul Gillespie, Yun He, Tai-An Lin, Sung-Sau So, HongYing Yun, Zhenshan Zhang
Life of this patent
Estimating the term…
Abstract
The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R1-R5 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
Claims28
A compound of formula I:
- or a pharmaceutically acceptable salt or ester thereof;
- wherein:
- X is a direct bond, oxygen, or —S(O)2—;
- and X is bonded to the ring containing Q by substitution of a hydrogen atom of a ring carbon atom;
- Q is carbon and W is carbon or nitrogen with the proviso that when W is nitrogen, the nitrogen is unsubstituted;
- R1 is hydrogen or methyl;
- R2 and R3 are bonded to the ring containing Q by substitution of a hydrogen atom of a ring carbon atom;
- and R2 and R3, independently of each other, are selected from the group consisting of:
- (1) hydrogen;
- (2) halogen;
- (3) lower alkyl optionally substituted by halogen;
- and
- (4) lower cycloalkyl optionally substituted by lower alkyl;
- R4 and R5 are bonded to the ring containing W by substitution of a hydrogen atom of a ring carbon atom;
- and R4 and R5, independently of each other, are selected from the group consisting of:
- (1) hydrogen;
- (2) hydroxyl;
- (3) halogen;
- (4) nitro;
- (5) cyano;
- (6) lower alkyl optionally substituted by halogen;
- (7) lower alkoxy optionally substituted by halogen;
- (8) lower cycloalkoxy;
- (9) lower heterocycloalkyloxy;
- (10) lower alkanoyl;
- (11) carbamoyl, lower alkylaminocarbonyl, or lower dialkylaminocarbonyl;
- (12) lower alkylcarbonylamino;
- (13) lower alkylsulfanyl or lower cycloalkylsulfanyl
- (14) lower alkylsulfinyl or lower cycloalkylsulfinyl;
- (15) lower alkylsulfonyl or lower cycloalkylsulfonyl;
- and
- (16) trimethylsilyl;
- and
- n is 1 or 2.
A compound selected from the group consisting of:
- {4-[3-(5-Methyl-[1,3,4]oxadiazol-2-yl)-benzenesulfonylamino]-4,5,6,7-tetrahydro-indazol-1-yl}-acetic acid;
- [4-(3-Benzoylamino-benzenesulfonylamino)-4,5,6,7-tetrahydro-indazol-1-yl]-acetic acid;
- and
- [(R)-4-(3-Benzenesulfonylamino-benzenesulfonylamino)-4,5,6,7-dihydro-indazol-1-yl]-acetic acid;
- or a pharmaceutically acceptable salt or ester thereof.
Dependencies are inferred from the claim text.